Sage Therapeutics was founded in 2010 and is headquartered in Cambridge, US

Chief Executive Officer

CFO

Chief Medical Officer

CSO

Chief Commercial Strategy Officer

Vice President of Pharmacology, Head of Biology

Sage Therapeutics has an office in Cambridge

Cambridge, US (HQ)

215 First Street

USD

## Net income (Q1, 2017) | (56.8 m) |

## EBIT (Q1, 2017) | (57.5 m) |

## Market capitalization (15-Aug-2017) | 3.2 b |

## Cash (31-Mar-2017) | 145.5 m |

Sage Therapeutics's current market capitalization is $3.2 b.

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## R&D expense | 24.1 m | 69.4 m | 120.8 m |

## General and administrative expense | 9.7 m | 25.3 m | 39.4 m |

## Operating expense total | 33.8 m | 94.7 m | 160.2 m |

## EBIT | (33.8 m) | (94.7 m) | (160.2 m) |

## Interest expense | 8 k | ||

## Interest income | 8 k | ||

## Net Income | (33.8 m) | (94.5 m) | (159 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## R&D expense | 12.9 m | 18.6 m | 17.5 m | 23.6 m | 26.1 m | 29.1 m | 45.2 m | ||

## General and administrative expense | 4 m | 6.5 m | 6.6 m | 7.1 m | 8.9 m | 9 m | 12.3 m | ||

## Operating expense total | 16.9 m | 25.1 m | 24.1 m | 30.7 m | 35 m | 38.1 m | 57.5 m | ||

## EBIT | (16.9 m) | (25.1 m) | (24.1 m) | (30.7 m) | (35 m) | (38.1 m) | (57.5 m) | ||

## Interest expense | 21 k | 41 k | |||||||

## Interest income | 21 k | 41 k | |||||||

## Net Income | (12 m) | (21.5 m) | (16.9 m) | (41.9 m) | (65.9 m) | (30.5 m) | (65.3 m) | (103.1 m) | (56.8 m) |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 127.8 m | 186.8 m | 168.5 m |

## Accounts Receivable | 35.6 m | ||

## Inventories | 1.1 m | 1.7 m | 5.1 m |

## Current Assets | 128.8 m | 188.5 m | 402.6 m |

## PP&E | 163 k | 286 k | 1.4 m |

## Total Assets | 129.7 m | 189 m | 404.5 m |

## Accounts Payable | 2.4 m | 5.2 m | 12.8 m |

## Current Liabilities | 7.8 m | 15.3 m | 35.2 m |

## Total Liabilities | 36 m | ||

## Additional Paid-in Capital | 188.7 m | 335 m | 689 m |

## Retained Earnings | (66.8 m) | (161.3 m) | (320.3 m) |

## Total Equity | 121.9 m | 173.7 m | 368.5 m |

## Financial Leverage | 1.1 x | 1.1 x | 1.1 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 49.1 m | 136.7 m | 113.2 m | 224.2 m | 204.9 m | 299.7 m | 189 m | 320.1 m | 145.5 m |

## Current Assets | 51.5 m | 137.8 m | 114.5 m | 227.5 m | 207.5 m | 302.6 m | 274.1 m | 434.7 m | 349 m |

## PP&E | 69 k | 134 k | 269 k | 285 k | 249 k | 865 k | 959 k | 1 m | 1.6 m |

## Total Assets | 51.7 m | 138 m | 115.5 m | 228.5 m | 208.4 m | 303.5 m | 275.6 m | 436.3 m | 351.2 m |

## Accounts Payable | 1.9 m | 2.2 m | 2.8 m | 5.2 m | 3.2 m | 4.5 m | 6 m | 5.2 m | 8.2 m |

## Current Liabilities | 3.9 m | 5 m | 8.9 m | 11 m | 10.3 m | 16 m | 18.3 m | 22.3 m | 31.9 m |

## Additional Paid-in Capital | 187.4 m | 190.2 m | 326.2 m | 330.9 m | 479.4 m | 483.8 m | 678.2 m | 695.6 m | |

## Retained Earnings | (44.8 m) | (54.5 m) | (83.7 m) | (108.7 m) | (132.8 m) | (191.9 m) | (226.6 m) | (264.4 m) | (377.1 m) |

## Total Equity | 132.9 m | 106.5 m | 217.5 m | 198.1 m | 287.5 m | 257.2 m | 413.7 m | 318.4 m | |

## Financial Leverage | 1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | (33.8 m) | (94.5 m) | (159 m) |

## Depreciation and Amortization | 51 k | 115 k | 281 k |

## Inventories | (715 k) | (681 k) | (3.4 m) |

## Accounts Payable | 441 k | 2.7 m | 7.8 m |

## Cash From Operating Activities | 119.7 m | 59 m | (118.7 m) |

## Purchases of PP&E | (128 k) | (198 k) | (1.4 m) |

## Cash From Investing Activities | (128 k) | (198 k) | (230.5 m) |

## Cash From Financing Activities | 146.9 m | 129.9 m | 331 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (12 m) | (21.5 m) | (16.9 m) | (41.9 m) | (65.9 m) | (30.5 m) | (65.3 m) | (103.1 m) | (56.8 m) |

## Depreciation and Amortization | 22 k | 35 k | 22 k | 54 k | 83 k | 41 k | 116 k | 199 k | |

## Accounts Payable | (385 k) | (6 k) | 343 k | 2.8 m | 808 k | (799 k) | 941 k | 116 k | 8.2 m |

## Cash From Operating Activities | (10.9 m) | (18.4 m) | (14.6 m) | (33 m) | (52.6 m) | (27.4 m) | (54.1 m) | (84.9 m) | |

## Purchases of PP&E | (5 k) | (83 k) | (110 k) | (181 k) | (160 k) | (341 k) | (835 k) | (901 k) | |

## Cash From Investing Activities | (5 k) | (83 k) | (110 k) | (181 k) | (160 k) | (341 k) | (84.4 m) | (112.1 m) | |

## Cash From Financing Activities | 52 m | 147.1 m | 112 k | 129.7 m | 129.8 m | 140.7 m | 140.7 m | 330.3 m |

Y, 2017 | |
---|---|

## Financial Leverage | 1.1 x |

July 12, 2016

* Sage reports positive top-line results including
demonstration of 30-day durability from phase 2 clinical trial
of Sage-547 in severe postpartum depression